je.st
news
Adaptimmune IPO Well Received By Wall Street With Plenty Of Upside Left
2015-05-09 12:27:58| Biotech - Topix.net
Adaptimmune Therapeutics made its initial public offering on May 6 for $17 per share. The company is a clinical trial stage biotech researching immunotherapies that use T-cell platform technology.
Tags: left
street
received
wall
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||